Zoetis Inc (ZTS) Actualités

Form 8-K - Current report

Zoetis Declares Second Quarter 2025 Dividend

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the second quarter of 2025. The dividend will be...

Zoetis Announces U.S. Label Update for Librela® (bedinvetmab injection), a Treatment to Control Canine Osteoarthritis (OA) Pain

Zoetis Plans to Immediately Implement Updated Label Based on U.S. Post-Approval Experience with Librela Company Remains Confident in the Safety...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2024 Financial Results

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin...

Form 8-K - Current report

Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference

Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph...

Form 3 - Initial statement of beneficial ownership of securities

Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize...